Kenvue, Retailers Ask Full Appeals Court to Rehear Tylenol Autism Ruling
KVUE sits 27% above its 52-week low of $14.02.
Summary
Kenvue and major pharmacy chains filed a petition for rehearing en banc with the 2nd Circuit, challenging the July 13 panel decision that revived over 500 Tylenol autism lawsuits. The defendants argue the panel improperly second-guessed the district judge's exclusion of three expert witnesses under Rule 702. The rehearing request is a long shot—the 2nd Circuit rarely reconsiders its own decisions—but it signals continued litigation risk for Kenvue. If denied, the cases proceed to discovery and potential trials, keeping a material overhang on the stock. The company is already navigating the Kimberly-Clark merger, and this legal uncertainty adds complexity to the deal's closing.
At the time of this announcement, KVUE was trading at $17.79 on NYSE in the Life Sciences sector, with a market capitalization of approximately $34.2B. The 52-week trading range was $14.02 to $20.13. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.